The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
Heather E Vezina1,2, Richard C Brundage2, Thomas E Nevins3, Henry H Balfour Jr1,31Department of Laboratory Medicine and Pathology, 2Department of Experimental and Clinical Pharmacology, 3Department of Pediatrics, University of Minnesota, Minneapolis, MN, USAAbs...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ad33092548b64543bf8046cd60a040b1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ad33092548b64543bf8046cd60a040b1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ad33092548b64543bf8046cd60a040b12021-12-02T03:09:57ZThe pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease1179-1438https://doaj.org/article/ad33092548b64543bf8046cd60a040b12009-12-01T00:00:00Zhttp://www.dovepress.com/the-pharmacokinetics-of-valganciclovir-prophylaxis-in-pediatric-solid--a3862https://doaj.org/toc/1179-1438Heather E Vezina1,2, Richard C Brundage2, Thomas E Nevins3, Henry H Balfour Jr1,31Department of Laboratory Medicine and Pathology, 2Department of Experimental and Clinical Pharmacology, 3Department of Pediatrics, University of Minnesota, Minneapolis, MN, USAAbstract: Antiviral prophylaxis with valganciclovir is used frequently in pediatric solid organ transplant patients to prevent Epstein–Barr virus (EBV)-induced infections and tissue-invasive disease including post-transplant lymphoproliferative disorder (PTLD). This approach is untested in clinical trials and valganciclovir dosing strategies in children are highly variable. Our objective was to characterize the pharmacokinetics of ganciclovir in the plasma of pediatric kidney and liver transplant patients taking valganciclovir for EBV prophylaxis. Virologic response was also evaluated. Ganciclovir was measured by liquid chromatography/ultraviolet detection. EBV DNA was quantified by TaqMan® polymerase chain reaction. NONMEM® VI was used for data analysis. Ganciclovir plasma profiles were consistent with a one-compartment model. Final model estimates of apparent oral clearance (L/h), apparent volume of distribution (L), and absorption rate constant were 7.33, 35.1, and 0.85, respectively. There was evidence of lower bioavailability in children younger than three years. All eight subjects achieved ganciclovir plasma concentrations above reported in vitro concentrations needed to inhibit EBV replication by 50%. However, four subjects had detectable EBV DNA with a median (range) of 18,300 (4,400 to 54,900) copies/mL of whole blood. These findings support the need for further studies of the clinical pharmacology and efficacy of valganciclovir for EBV prophylaxis.Keywords: valganciclovir, ganciclovir, pharmacokinetics, Epstein–Barr virus, pediatrics, solid organ transplantation Heather E VezinaRichard C BrundageThomas E Nevinset alDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2010, Iss default, Pp 1-7 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
Therapeutics. Pharmacology RM1-950 Heather E Vezina Richard C Brundage Thomas E Nevins et al The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease |
| description |
Heather E Vezina1,2, Richard C Brundage2, Thomas E Nevins3, Henry H Balfour Jr1,31Department of Laboratory Medicine and Pathology, 2Department of Experimental and Clinical Pharmacology, 3Department of Pediatrics, University of Minnesota, Minneapolis, MN, USAAbstract: Antiviral prophylaxis with valganciclovir is used frequently in pediatric solid organ transplant patients to prevent Epstein–Barr virus (EBV)-induced infections and tissue-invasive disease including post-transplant lymphoproliferative disorder (PTLD). This approach is untested in clinical trials and valganciclovir dosing strategies in children are highly variable. Our objective was to characterize the pharmacokinetics of ganciclovir in the plasma of pediatric kidney and liver transplant patients taking valganciclovir for EBV prophylaxis. Virologic response was also evaluated. Ganciclovir was measured by liquid chromatography/ultraviolet detection. EBV DNA was quantified by TaqMan® polymerase chain reaction. NONMEM® VI was used for data analysis. Ganciclovir plasma profiles were consistent with a one-compartment model. Final model estimates of apparent oral clearance (L/h), apparent volume of distribution (L), and absorption rate constant were 7.33, 35.1, and 0.85, respectively. There was evidence of lower bioavailability in children younger than three years. All eight subjects achieved ganciclovir plasma concentrations above reported in vitro concentrations needed to inhibit EBV replication by 50%. However, four subjects had detectable EBV DNA with a median (range) of 18,300 (4,400 to 54,900) copies/mL of whole blood. These findings support the need for further studies of the clinical pharmacology and efficacy of valganciclovir for EBV prophylaxis.Keywords: valganciclovir, ganciclovir, pharmacokinetics, Epstein–Barr virus, pediatrics, solid organ transplantation |
| format |
article |
| author |
Heather E Vezina Richard C Brundage Thomas E Nevins et al |
| author_facet |
Heather E Vezina Richard C Brundage Thomas E Nevins et al |
| author_sort |
Heather E Vezina |
| title |
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease |
| title_short |
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease |
| title_full |
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease |
| title_fullStr |
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease |
| title_full_unstemmed |
The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease |
| title_sort |
pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for epstein–barr virus disease |
| publisher |
Dove Medical Press |
| publishDate |
2009 |
| url |
https://doaj.org/article/ad33092548b64543bf8046cd60a040b1 |
| work_keys_str_mv |
AT heatherampnbspevezina thepharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease AT richardcbrundage thepharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease AT thomasampnbspenevins thepharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease AT etal thepharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease AT heatherampnbspevezina pharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease AT richardcbrundage pharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease AT thomasampnbspenevins pharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease AT etal pharmacokineticsofvalganciclovirprophylaxisinpediatricsolidorgantransplantpatientsatriskforepsteinampndashbarrvirusdisease |
| _version_ |
1718401940452278272 |